No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
www.jbpharma.comNo one on the platform currently holds JBCHEPHARM.NS.
No tracked institution reports a position in JBCHEPHARM.NS as of their last filing.
No one on the platform has traded JBCHEPHARM.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.0% | 16.9% | 15.5% | — | — | — |
| Rev. Growth % | 7.4% | 15.5% | ||||
| Profit Margin % | 17.1% | 15.9% | 15.3% | |||
| Free Cash Flow Margin % | 15.1% | 5.0% | 6.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $46.4B | +8.3% | $56.20 | $49.46–$62.28 | — | 7 |
| 2028 | $55.5B | +19.7% | $75.70 | $70.25–$84.12 | — | 7 |
| 2029 | $57.1B | +2.8% | $93.60 | $87.81–$103.05 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-11 | $9.90 | $7.70 | -22.2% |
| 2026-02-02 | $12.30 | $12.70 | +3.3% |
| 2025-11-11 | $12.90 | $13.30 | +3.1% |
| 2025-07-30 | $13.60 | $13.70 | +0.7% |
| 2025-05-14 | $8.30 | $9.41 | +13.4% |
| 2025-02-04 | $10.20 | $10.40 | +2.0% |
| 2024-11-06 | $10.80 | $11.00 | +1.9% |
| 2024-08-08 | $9.80 | $11.16 | +13.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| JBCHEPHARM.NSJ. B. Chemicals & Pharmaceuticals Limited | $2416.10 | +0.30% | $387.9B | — |
| AJANTPHARM.NSAjanta Pharma Limited | $3510.40 | -0.65% | $438.6B | — |
| ALEMBICLTD.NSAlembic Limited | $100.51 | -3.66% | $25.8B | — |
| ALKEM.NSAlkem Laboratories Limited | $5161.00 | +1.44% | $617.1B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited |
| $824.75 |
| +1.70% |
| $162.1B |
| — |
| AUROPHARMA.NSAurobindo Pharma Limited | $1660.00 | -1.18% | $955.1B | — |
| BALPHARMA.NSBal Pharma Limited | $107.44 | +0.02% | $1.7B | — |
Source: Financial Modeling Prep · peers by sector/industry